IMR Press / EJGO / Volume 22 / Issue 1 / pii/2001119

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Side-effects of paclitaxel therapy in ovarian cancer patents

Show Less
1 Gynecologic Oncology Department, National Institute of Oncology, Budapest, Hungary
Eur. J. Gynaecol. Oncol. 2001, 22(1), 81–84;
Published: 10 February 2001

Objective: Since premedication with HI, H2 receptor antagonists and steroids fewer side-effects of paclitaxel (PTXL) che­motherapy have been published. The authors summarize the literature and their own experience. Materials and methods: 23 patients with stage III ovarian cancer were treated with second-line chemotherapy of PTXL and car­boplatin (CRB) with the doses of 175 mg/m2, 3 h and AUC 5 mg/ml-min, respectively. The side-effects of treatment are evaluated in a prospective non-randomized study. Results: Rare toxicity in hemoglobin (G0-15%, G1-62%, G2-12% and G4-4%) and leukocyte levels (G0-35%, G 1-25%, G2-29%, G3-11 % and G4-0%) were detected. There was no definite change found in platelet count (G0-89.5%, G 1-10.5%), and moreover in 15.8% of the patients the controlled platelet count was higher than the normal laboratory range. Liver enzymes, serum creatinine and carbamide levels in each case were within the normal range (GO). One patient complained of severe neuropathy (nervus oculomotorius paresis), and another one developed severe ECG abnormalities. Conclusions: When suitable premedication is applied few side-effects of PTXL therapy are reported.

Ovarian cancer
Back to top